BDTX-189 CAS No.:2414572-47-5

Welcome to our product introduction of BDTX-189, a cutting-edge compound that promises to revolutionize the field of cancer treatment. As a Chinese manufacturer, we are proud to offer this breakthrough product as part of our commitment to producing high-quality and effective medications for clients around the world.

BDTX-189, also known by its chemical name CAS No.:2414572-47-5, is a small molecule inhibitor that targets a specific protein called E3 ubiquitin ligase. This protein plays a crucial role in cancer cell growth and proliferation, making it a promising target for cancer therapy.

Our researchers have spent years developing and refining this unique compound, using cutting-edge techniques and the latest in scientific research to create a product that can selectively inhibit E3 ubiquitin ligase while leaving other proteins unaffected. This precision targeting allows us to deliver a potent anti-cancer therapy with minimal side effects and maximum efficacy.

BDTX-189 has undergone extensive testing in preclinical models, and the results have been overwhelmingly positive. In animal studies, this compound has demonstrated significant anti-tumor activity, inhibiting tumor growth and reducing tumor volume in a variety of cancer types.

One of the key advantages of BDTX-189 is its versatility. This compound has been shown to be effective against a wide range of cancer types, including breast, lung, liver, colorectal, and pancreatic cancers. This broad spectrum of activity makes it a promising candidate for combination therapies, allowing it to be used in conjunction with other cancer drugs to improve overall treatment outcomes.

In addition to its anti-tumor activity, BDTX-189 has also been shown to be well-tolerated in preclinical studies. This is a critical consideration when it comes to cancer therapy, as many traditional chemotherapy drugs can cause significant side effects such as nausea, fatigue, and hair loss. By minimizing these side effects, BDTX-189 offers a more tolerable treatment option for cancer patients, improving their quality of life and potentially increasing treatment adherence.

At our manufacturing facility in China, we use state-of-the-art equipment and processes to ensure the highest level of product quality and purity. Our commitment to quality control and rigorous testing procedures means that you can trust that every batch of BDTX-189 will meet or exceed industry standards, providing you with a reliable and effective medication that you and your patients can count on.

In conclusion, BDTX-189 represents a significant advance in cancer treatment, offering a precise and versatile therapy with minimal side effects and maximum efficacy. We are proud to offer this innovative product to our clients around the world, and we are confident that it will prove to be a game-changer in the fight against cancer. If you are interested in learning more about BDTX-189 or would like to place an order, please don't hesitate to contact us. Thank you for considering our product for your cancer therapy needs.

Chemical Structure : BDTX-189

CAS No.: 2414572-47-5

 

 

 

 

BDTX-189 (Tuxobertinib, BDTX189)

Catalog No.: URK-V1278 Only Used For Lab.

BDTX-189 (Tuxobertinib) is a potent, selective, irreversible inhibitor of allosteric EGFR and HER2 mutant variants.

Biological Activity

BDTX-189 (Tuxobertinib) is a potent, selective, irreversible inhibitor of allosteric EGFR and HER2 mutant variants.
BDTX-189 (Tuxobertinib) shows KD value s of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively.
BDTX-189 (Tuxobertinib) inactivates multiple allosteric ERBB mutants in vivo, achieves dose-dependent regression of allosteric HER2 and EGFR tumors.

Physicochemical Properties

References

1. Elizabeth Buck, et al. BDTX-189, a Potent and Selective Inhibitor of Allosteric EGFR and HER2 Oncogenic Mutations.

URK-V1278_COA

URK-V1278_SDS

URK-V1278_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We are committed to providing our customers with the best possible Tyrosine Kinase Library products and services.
• Our company has been advocating the enterprise concept of 'sincere cooperation and common development'.
• Our Tyrosine Kinase Library products are designed to be durable and long-lasting.
• We actively promote the harmonious development of the company, society and environment, and establish and improve the corporate social responsibility system.
• We take customer feedback seriously and are always looking for ways to improve our Tyrosine Kinase Library products and services.
• In order to meet the requirements of the market and constantly update the products, we constantly develop new products on the basis of fully summarizing the characteristics of the original products.
• We value our customers and strive to build long-term relationships based on trust and mutual respect.
• On the basis of insisting on independent research and development, we carry out open cooperation. The company is committed to the field of BDTX-189 CAS No.:2414572-47-5 and provides professional products and services to customers at home and abroad.
• Our team is always available to answer any questions you may have about our Tyrosine Kinase Library products.
• Our company has established long-term cooperative relations with many manufacturers and can provide a steady stream of goods for new and old customers!

Hot Tags: bdtx-189 cas no.:2414572-47-5, China bdtx-189 cas no.:2414572-47-5, agonists for cell signaling studies, epigenetic library for epigenetic repression, epigenetic library for epigenetic network, inhibitors for drug discovery, inhibitors for cytoskeletal regulation, epigenetic library for epigenetic analysis of epigenetic mechanism research